Literature DB >> 33285023

Missense PDSS1 mutations in CoenzymeQ10 synthesis cause optic atrophy and sensorineural deafness.

Francesca Nardecchia1, Agnese De Giorgi1, Flavia Palombo2, Claudio Fiorini2, Anna M De Negri3, Valerio Carelli2,4, Leonardo Caporali2, Vincenzo Leuzzi5.   

Abstract

CoenzymeQ10 is one of the main cellular antioxidants and an essential lipid involved in numerous cell reactions, such as energy production and apoptosis modulation. A large number of enzymes are involved in CoQ10 biosynthesis. Mutations in the genes encoding for these enzymes cause a CoQ10 deficiency, characterized by neurological and systemic symptoms. Here we describe two young sisters with sensorineural deafness followed by optic atrophy, due to a novel homozygous pathogenic variant in PDSS1. The visual system seems to be mainly involved when the first steps of CoQ10 synthesis are impaired (PDSS1, PDSS2, and COQ2 deficiency).
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Year:  2020        PMID: 33285023     DOI: 10.1002/acn3.51232

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


  2 in total

1.  Biallelic variants in coenzyme Q10 biosynthesis pathway genes cause a retinitis pigmentosa phenotype.

Authors:  Neringa Jurkute; Francesca Cancellieri; Lisa Pohl; Catherina H Z Li; Robert A Heaton; Janine Reurink; James Bellingham; Mathieu Quinodoz; Georgia Yioti; Maria Stefaniotou; Marianna Weener; Theresia Zuleger; Tobias B Haack; Katarina Stingl; Carel B Hoyng; Omar A Mahroo; Iain Hargreaves; F Lucy Raymond; Michel Michaelides; Carlo Rivolta; Susanne Kohl; Susanne Roosing; Andrew R Webster; Gavin Arno
Journal:  NPJ Genom Med       Date:  2022-10-20       Impact factor: 6.083

2.  A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC.

Authors:  Zuqin Rao; Heng Li; Wenchao Yao; Qiang Wang; Biao Ma; Dongbo Xue; Xianzhi Meng
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.